TRAF3改变在del-3'IGH慢性淋巴细胞白血病中频繁出现并定义具有不良临床特征的特定亚组
本研究对871例慢性淋巴细胞白血病(CLL)检测IGH断裂分离探针,54例(6.2%)存在300 kb的3'IGH缺失(del-3'IGH CLL),该缺失与更短的首治时间(TFT)相关。对317例未治疗CLL(54例del-3'IGH、263例对照)行二代测序,del-3'IGH组NOTCH1(30%)、ATM(20%)、RAS信号通路基因(15%)和TRAF3(13%)突变频率高,TRAF3突变发生率显著高于对照组(p < .001),TRAF3缺失在14q缺失CLL中高度富集(p < .001)。
要点
- 871例CLL中54例(6.2%)存在300 kb的3'IGH缺失,与更短的首治时间相关。
- del-3'IGH组TRAF3突变发生率为13%,显著高于对照组(p < .001)。
- TRAF3双等位失活是全CLL队列中首治时间的独立危险因素。
核心结论
- del-3'IGH CLL具有涉及多条分子通路的独特遗传学特征,其特征为TRAF3双等位失活,导致该亚组患者预后明显不良。
研究设计与样本
- 共对871例CLL进行IGH断裂分离探针检测,其中54例(6.2%)存在300 kb的3'IGH缺失。
- 对317例未治疗CLL(54例del-3'IGH、263例对照)进行二代测序突变分析,并作拷贝数分析。
主要发现
- del-3'IGH组突变频率为NOTCH1(30%)、ATM(20%)、RAS信号通路基因(BRAF、KRAS、NRAS、MAP2K1)(15%)和TRAF3(13%)。
- TRAF3突变发生率在del-3'IGH CLL中显著高于对照组(p < .001)。
- TRAF3缺失在14q缺失的CLL中高度富集(p < .001),提示经缺失和突变导致该基因完全双等位失活。
- 上述基因突变从总生存(NOTCH1、ATM和RAS信号通路基因)和首治时间(TRAF3)两方面负向细化del-3'IGH CLL的预后。
- TRAF3双等位失活是全CLL队列中首治时间的独立危险因素。
关键数值与推荐
- del-3'IGH定义为300 kb的3'IGH缺失,在871例CLL中占54例(6.2%)。
- del-3'IGH组与对照组TRAF3突变发生率比较的p < .001。
- 14q缺失CLL中TRAF3缺失富集的p < .001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Interstitial 14q32 deletions involving IGH gene are infrequent events in chronic lymphocytic leukemia (CLL), affecting less than 5% of patients. To date, little is known about their clinical impact and molecular underpinnings, and its mutational landscape is currently unknown. In this work, a total of 871 CLLs were tested for the IGH break-apart probe, and 54 (6.2%) had a 300 kb deletion of 3'IGH (del-3'IGH CLLs), which contributed to a shorter time to first treatment (TFT). The mutational analysis by next-generation sequencing of 317 untreated CLLs (54 del-3'IGH and 263 as the control group) showed high mutational frequencies of NOTCH1 (30%), ATM (20%), genes involved in the RAS signaling pathway (BRAF, KRAS, NRAS, and MAP2K1) (15%), and TRAF3 (13%) within del-3'IGH CLLs. Notably, the incidence of TRAF3 mutations was significantly higher in del-3'IGH CLLs than in the control group (p < .001). Copy number analysis also revealed that TRAF3 loss was highly enriched in CLLs with 14q deletion (p < .001), indicating a complete biallelic inactivation of this gene through deletion and mutation. Interestingly, the presence of mutations in the aforementioned genes negatively refined the prognosis of del-3'IGH CLLs in terms of overall survival (NOTCH1, ATM, and RAS signaling pathway genes) and TFT (TRAF3). Furthermore, TRAF3 biallelic inactivation constituted an independent risk factor for TFT in the entire CLL cohort. Altogether, our work demonstrates the distinct genetic landscape of del-3'IGH CLL with multiple molecular pathways affected, characterized by a TRAF3 biallelic inactivation that contributes to a marked poor outcome in this subgroup of patients.
引用
- Pérez-Carretero C, Hernández-Sánchez M, González T, et al. TRAF3 alterations are frequent in del-3'IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features. Am J Hematol. 2022. PMID: 35472012. doi:10.1002/ajh.26578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。